Page 19 - 2020_01-Haematologica-web
P. 19
Editorials
However, as HHT has been shown to bind to SP1, and SP1 is a widely expressed transcription factor whose expression is not restricted to AML cells, it is not surpris- ing that HHT treatment can have considerable side effects, including myelosuppression. Another unan- swered question is whether HHT only binds to SP1 or whether it also binds to other cellular proteins which, again, could cause side effects and adverse reactions.
Although it is unlikely that HHT will provide a cure for AML, it could become an important component of ever more diversified and targeted treatment strategies in this disease. The effectiveness of HHT and its therapeutic window need to be assessed rigorously in controlled clin- ical trials. These should be accompanied by a detailed genetic work up to identify those AML subgroups that are especially responsive to HHT therapy.
References
1. Burnett A, Wetzler M, and Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-494.
2. Platzbecker U, Avvisati G, Cicconi L, et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol. 2017;35(6):605-612.
3. Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016;34(24):2851-2857.
4. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
5. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209-2221.
6. Powell RG, Weisleder D, and Smith CR. Antitumor alkaloids for Cephalataxus harringtonia: structure and activity. J Pharm Sci. 1972;61(8):1227-1230.
7. Li C, Dong L, Su R, et al. Homoharringtonine exhibits potent anti- tumr effect and modulates DNA epigenome n acute myeloid leukemia by targeting SP1/TET1/5hmC. Haematologica. 2020; 105(1):148-160.
8. Jin J, Jiang DZ, Mai WY, et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia. 2006;20(8):1361-1367.
9. Jin J, Wang JX, Chen FF, et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a mul- ticentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013;14(7):599-608.
10. Nazha A, Kantarjian H, Cortes J, and Quintás-Cardama A. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia. Expert Opin Pharmacother. 2013;14(14):1977- 1986.
11. Gürel G, Blaha G, Moore PB, and Steitz TA. U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tia- mulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol. 2009;389(1):146-156.
12. WuXandZhangY.TET-mediatedactiveDNAdemethylation:mech- anism, function and beyond. Nat Rev Genet. 2017;18(9):517-534.
13. van Riggelen J, Yetil A and Felsher DW. MYC as a regulator of ribo-
some biogenesis and protein synthesis. Nat Rev Cancer.
2010;10(4):301-309.
14. Tiong IS and Wei AH. New drugs creating new challenges in acute
myeloid leukemia. Genes Chromosomes Cancer. 2019;58(12):903- 914.
haematologica | 2020; 105(1)
9
